Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025161 | 1.00 | GLP1R (0.37) | GLP1RGRIN1GRIN2B | |
| SCHEMBL25024765 | 1.00 | GLP1R (0.37) | GLP1RGRIN1GRIN2B | |
| SCHEMBL25024754 | 0.93 | GLP1R (0.36) | GLP1R | |
| SCHEMBL25025360 | 0.93 | GLP1R (0.36) | GLP1R | |
| SCHEMBL25025176 | 0.93 | GLP1R (0.36) | GLP1R | |
| SCHEMBL25024770 | 0.92 | GLP1R (0.32) | GLP1R | |
| SCHEMBL25025283 | 0.92 | GLP1R (0.32) | GLP1R | |
| SCHEMBL25023797 | 0.92 | GLP1R (0.32) | GLP1R | |
| SCHEMBL25025307 | 0.91 | GLP1R (0.32) | GLP1RGRIN1GRIN2B | |
| SCHEMBL25025186 | 0.90 | GLP1R (0.32) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | ECCOGENE INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | GLP1R 1/4885GRIN1 835/4885GRIN2B 2008/4885 |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | GLP1R, SLC5A1, GIPR | GLP1R 1/4885GRIN1 812/4885GRIN2B 2250/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | GLP1R 1/4885GRIN1 835/4885GRIN2B 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.